175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
Late-breaking abstract at ERS Congress provides new estimate from leading researchers and key opinion leaders
These statistics are based on the latest scoring rules for determining one’s apnoea-hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life.
The new global prevalence is nearly tenfold higher than the previous one - 100 million - estimated by the World Health Organization in 2007.
European countries with the highest prevalence are:
· Russia, 40 million
· Germany, 26 million
· France, 24 million
· Ukraine, 13 million
· Spain, 9 million
· United Kingdom, 8 million
“This data is a warning call to Europe’s doctors and other care providers to properly identify, screen and diagnose these people so they can get the life-changing treatment they need,” said Dr. Adam Benjafield, lead researcher and ResMed’s vice president of Medical Affairs.
Benjafield said one sign of an at-risk patient is whether they have a related chronic medical condition:
· 83% of people with drug-resistant hypertension have sleep apnoea
· 77% of people with obesity
· 76% of people with chronic heart failure
· 72% of people with type 2 diabetes
· 62% of people with a prior stroke
· 49% of people with atrial fibrillation
“Doctors should screen their patients if they have any of these conditions,” said Benjafield, “especially if a patient has exhibited sleep apnoea-related symptoms like snoring, daytime sleepiness or frequent nighttime urination.”
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnoea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005278/en/
Website: https://www.resmed.com/ap/en/index.html
Contact
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
For investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
This news is a press release provided by ResMed Inc..
-
2020년 9월 2일 16:00
